Abstract
Positron Emission Tomography (PET) can be used to assess changes of endogenous neurotransmitters induced by pharmacological or physiological challenges and has been successfully applied to the study of the dopaminergic system, and, to a lower extent, to the serotonergic, opioid and cholinergic systems. This review first introduces the principles underlying the assessment of fluctuations of endogenous neurotransmitters with PET and then summarizes the main results obtained for dopamine, with emphasis on clinical studies. The studies of serotonin, opioid peptides, acetylcholine and the few studies dealing with other neurotransmitters (GABA, glutamate) are subsequently reviewed. In conclusion the chances of successfully imaging endogenous neurotransmitters with PET as well as possible trends for the future are discussed.
Keywords: Binding potential (BP), competition model, endogenous neurotransmitter (EN), internalization model, pharmacological challenge, positron emission tomography (PET), serotonin, opioid peptides, acetylcholine, Parkinson's disease, amphetamine, epidepride, methylspiperone, fallypride, Antagonist Tracers
Current Psychopharmacology
Title: Imaging Endogenous Neurotransmitters In Vivo with Positron Emission Tomography Displacement Studies
Volume: 1
Author(s): Giampaolo Tomasi
Affiliation:
Keywords: Binding potential (BP), competition model, endogenous neurotransmitter (EN), internalization model, pharmacological challenge, positron emission tomography (PET), serotonin, opioid peptides, acetylcholine, Parkinson's disease, amphetamine, epidepride, methylspiperone, fallypride, Antagonist Tracers
Abstract: Positron Emission Tomography (PET) can be used to assess changes of endogenous neurotransmitters induced by pharmacological or physiological challenges and has been successfully applied to the study of the dopaminergic system, and, to a lower extent, to the serotonergic, opioid and cholinergic systems. This review first introduces the principles underlying the assessment of fluctuations of endogenous neurotransmitters with PET and then summarizes the main results obtained for dopamine, with emphasis on clinical studies. The studies of serotonin, opioid peptides, acetylcholine and the few studies dealing with other neurotransmitters (GABA, glutamate) are subsequently reviewed. In conclusion the chances of successfully imaging endogenous neurotransmitters with PET as well as possible trends for the future are discussed.
Export Options
About this article
Cite this article as:
Tomasi Giampaolo, Imaging Endogenous Neurotransmitters In Vivo with Positron Emission Tomography Displacement Studies, Current Psychopharmacology 2012; 1 (1) . https://dx.doi.org/10.2174/2211556011201010029
DOI https://dx.doi.org/10.2174/2211556011201010029 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Applicability of Microarray Technology in the Diagnosis, Prognostic Stratification, Treatment and Clinical Surveillance of Cervical Adenocarcinoma
Current Pharmaceutical Design Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine Biomarkers and Osteosarcoma and IGF
Recent Patents on Biomarkers The Polyhedric Abl Kinases and their Pharmacologic Inhibitors
Current Enzyme Inhibition Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets Pharmacological Modulation of Diacylglycerol-Sensitive TRPC3/6/7 Channels
Current Pharmaceutical Biotechnology Transcription Factors as Targets for Cancer Therapy: AP-1 a Potential Therapeutic Target
Current Cancer Therapy Reviews Short-Chain Fatty Acid Inhibitors of Histone Deacetylases: Promising Anticancer Therapeutics?
Current Cancer Drug Targets The Neuroprotective Role of PEDF: Implication for the Therapy of Neurological Disorders
Current Molecular Medicine Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry Retinoic Acid Signaling in P19 Stem Cell Differentiation
Anti-Cancer Agents in Medicinal Chemistry Molecular Mechanism of Anti-tumor Effect by Triptolide in Hematological Malignancies
Current Signal Transduction Therapy Network Medicine and High Throughput Screening
Current Drug Discovery Technologies Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases
Current Pharmaceutical Design Destabilizing Aneuploidy by Targeting Cell Cycle and Mitotic Checkpoint Proteins in Cancer Cells
Current Drug Targets Cystine Dimethyl Ester Induces Apoptosis Through Regulation of PKC-δ and PKC-ε in Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients
Current Pharmaceutical Biotechnology Flavonoids with Therapeutic Potential in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Antitumor Properties of Natural Compounds and Related Molecules
Recent Patents on Anti-Cancer Drug Discovery Understanding Mouse Skin Carcinogenesis through Transgenic Approaches
Current Genomics